EUCTR2016-003479-22-Outside-EU/EEA进行中（未招募）1 期
Clinical assessment of fluticasone propionate/ salmeterol xinafoate HFA MDI in 6-month to 4-year-old Japanese patients with bronchial asthma
GlaxoSmithKline Research and development Ltd0 个研究点目标入组 370 人开始时间: 2016年11月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 370
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria
- •Specific information regarding warnings, precautions, contraindications, adverse events, and other pertinent information on the GSK investigational product or other study treatment that may impact subject eligibility is provided in the product label, add other pertinent documents.
- •Deviations from inclusion criteria are not allowed because they can potentially jeopardise the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.
- •Subjects eligible for enrolment in the study must meet all of the following criteria:
- •1.Obtaining consent: The written informed consent must be obtained from his/her parent or legally acceptable representative. If the investigator (or subinvestigator) obtains the oral consent from the patient, the investigator (or subinvestigator) should record so in the informed consent form which is signed by his/her parent or legally acceptable representative.
- •2.Race: Japanese
- •3.Age: = 6 months and =4 years at Visit 1.
- •4.Sex: Male and premenarcheal female. Premenarcheal females are defined as any female who has yet to have menstruation.
- •5.Patients: Outpatient
- •6.Diagnosis of asthma: Diagnosis of infantile bronchial asthma is made by reference to JPGL2012 and the rationale is documented.
- •As for diagnosis of children of < 2 years old, the following description in JPGL2012 should be referenced [Japanese Society of Pediatric Allergy and Clinical Immunology, 2011].
- •- There are 3 or more episodes of obvious expiratory wheezing, regardless of the presence of respiratory tract infection. It is also needed to confirm that there is asymptomatic period for about a week between episodes.
- •In addition to this finding, if there is at least one of the following findings, it is more helpful to diagnose infantile asthma,
- •- At least one of parents is diagnosed with bronchial asthma by a physician (including past history).
- •- Specific IgE antibody for inhalation antigen is detected in at least one of parents.
- •- The diseased child is diagnosed with atopic dermatitis by a physician (including past history).
- •- Specific IgE antibody for inhalation antigen is detected in the diseased child.
- •- High serum IgE level in the diseased child or his/her family (serum IgE level should be determined in consideration of age).
- •- Eosinophils and creola bodies found in the sputum (increased eosinophils in nasal discharge and peripheral blood will be referenced).
- •- Expiratory wheezing occurs when seemingly there is no airway infection.
- •- Expiratory wheezing and labored respiration or oxygen saturation are improved after beta-2 stimulant inhalation.
- •7.Treatment of asthma: A patient who needs to be treated with ICS/LABA and fulfils all of the following conditions,
- •At least one documented asthma exacerbation in that the patient treated with systemic glucocorticosteroids, aminophylline intravenous drip infusion (continuous drip infusion) or continuous isoproterenol inhalation within the 12 months prior to Visit 1. Or a well-documented continuous treatment with ICS (FP 200-400 micro g daily or equivalent) within 12 months prior to Visit 1.
- •The patient has not received systemic glucocorticosteroids, aminophylline intravenous drip infusion (continuous drip infusion), ICS (FP > 200 micro g daily or equivalent) or continuous isoproterenol inhalation within 4 weeks prior to Visit 1.
- •Are the trial subjects under 18? yes
排除标准
- •Exclusion Criteria
- •Deviations from exclusion criteria are not allowed because they can potentially jeopardise the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.
- •Subjects meeting any of the following criteria must not be enrolled in the study:
- •1.Concomitant medication (infectious diseases): A patient who had upper or lower respiratory tract infection and received concomitant medication within 2 weeks prior to Visit 1.
- •2.Infectious diseases: A patient who has confirmatory diagnosis of upper or lower respiratory tract infection at Visit 1; or a patient who has or is suspected to have deep mycosis or infection for which no effective antibacterial agent is available; or a patient who is suspected to have RS virus infection and cannot be identified to be negative for RS virus antigen.
- •3.Respiratory comorbidities: A patient who has respiratory disorder other than bronchial asthma, and the respiratory disorder is likely to have an impact on the assessment of efficacy in this study.
- •4.Liver disease: A patient who has unstable liver disease or chronic stable hepatitis B, receiving immunosuppressive agents due to risk of hepatitis B reactivation.
- •5.Other comorbidities: A patient who has malformation/foreign particle in an airway; or subjects who have known, pre-existing, clinically significant gastroesophageal reflux disease, endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological or any other abnormalities that are poorly controlled with standard treatment.
- •6.Drug allergy/ hypersensitivity: A patient who has or is suspected to have hypersensitivity to study medications, rescue medication or any ingredients of them.
- •7.Other studies/ study drug: A patient who participated in other studies/ trials and was treated with other investigational product(s) and 1 month has not elapsed at Visit 1 or the period of five-fold of the half-lives (t½) has not elapsed yet.
- •8.ECG: As for the patients who has evaluable ECG data at Visit 1, QTc(F) is =450 msec. If the first assessment meets this criterion, ECG should be measured two more times with interval after the first ECG, and the mean value of the three assessments will be used for judgement.
- •As for the patients who do not have evaluable ECG data at Visit 1, if the patient has known prolonged QTc (=450 msec, any correction is valid), the patient will be excluded.
- •9.Other: A patient who is child in care (including foster parent system), or whom the investigator (or subinvestigator) judges inappropriate for the study.
研究者
相似试验
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDEUCTR2017-004369-29-ESGlaxoSmithKline, S.A.3,000
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2017-004369-29-NLGlaxoSmithKline Research & Development Limited3,341
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2017-004369-29-GBGlaxoSmithKline Research & Development Limited3,000
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2017-004369-29-SEGlaxoSmithKline Research & Development Limited3,000
已完成
4 期
The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY ELLIPTA) when Compared with Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients within a Usual Care Setting.(study 206854)NL-OMON48721GlaxoSmithKline700